|Bid||11.47 x 1000|
|Ask||0.00 x 0|
|Day's Range||15.86 - 16.19|
|52 Week Range||11.02 - 17.99|
|PE Ratio (TTM)||13.68|
|Earnings Date||Apr 25, 2018 - Apr 30, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||13.25|
A significant reduction in the risk of on-treatment all-cause mortality was observed for both inhaled corticosteroid containing arms compared to Anoro. Dave Allen, Head, Respiratory Therapy Area R&D, GSK, said, “Reducing exacerbations to keep patients out of hospital is a key goal of COPD management alongside improving lung function and quality of life. The IMPACT study shows how Trelegy Ellipta can help patients with a history of exacerbation achieve these goals.
GlaxoSmithKline[ticker symb=GSK] partner Innoviva[ticker symb=INVA] is trying to buck the market correction and finish a new base. The biotech stock recently received new European Union approval for Relvar Ellipta, an asthma drug Innoviva developed with GSK. Last month, London-based GSK and California-based Innoviva announced that the European Commission approved a label upgrade for Relvar Ellipta. Known as Breo Ellipta in...
Companies, such as Innoviva, trading at a market price below their true values are considered to be undervalued. Investors can determine how much a company is worth based on howRead More...
Looking to enhance your portfolio with high-growth, financially-robust stocks, but not sure where you should even begin? Stocks such as Oasis Midstream Partners and Versum Materials are deemed to beRead More...
Short interest is moderate for INVA with between 5 and 10% of shares outstanding currently on loan. The net inflows of $307 million over the last one-month into ETFs that hold INVA are among the lowest of the last year and appear to be slowing.
Innoviva Inc (NASDAQ:INVA), a pharmaceuticals company based in United States, led the NasdaqGS gainers with a relatively large price hike in the past couple of weeks. As a stock withRead More...
GlaxoSmithKline plc and Innoviva, Inc. today announced that the European Commission has approved a label update for the use of once-daily Relvar Ellipta , an inhaled corticosteroid / long-acting β2-agonist combination, in patients whose asthma is already adequately controlled on both an inhaled corticosteroid and long-acting β2-agonist.
NEW YORK, March 06, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
Short interest is moderate for INVA with between 5 and 10% of shares outstanding currently on loan. The net inflows of $296 million over the last one-month into ETFs that hold INVA are among the lowest of the last year and appear to be slowing.
The latest earnings release Innoviva Inc’s (NASDAQ:INVA) announced in December 2017 signalled that the business experienced a major tailwind, more than doubling its earnings from the prior year. Investors mayRead More...
GlaxoSmithKline plc and Innoviva, Inc. today announced the submission of the landmark IMPACT data to the European Medicines Agency as part of a type II variation to support an expanded label for Trelegy Ellipta in Europe for the maintenance treatment of moderate to severe chronic obstructive pulmonary disease .
Follows Termination of CEO Mike Aguiar GREENWICH, Conn. , Feb. 13, 2018 /PRNewswire/ -- Sarissa Capital Management LP announced today that Sarissa Capital has entered into an agreement with Innoviva, Inc. ...
U.S. respiratory drug company Innoviva Inc has reached a settlement with activist hedge fund Sarissa Capital Management LP to replace its board of directors and remove the threat of a new proxy contest, people familiar with the matter said on Monday. The settlement comes just two months after a Delaware judge handed Sarissa a legal victory by installing two of the fund's nominees to Innoviva's board of directors. Sarissa had sued Innoviva, accusing it of backing out last April of a settlement that Sarissa agreed to end its previous proxy contest.
The Brisbane, California-based company said it had profit of 45 cents per share. The results beat Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was ...
Innoviva, Inc. today reported financial results for the fourth quarter and full year 2017. Gross royalties earned on net sales of RELVAR®/BREO® ELLIPTA®, ANORO® ELLIPTA® and TRELEGY® ELLIPTA® from Glaxo Group Limited during the fourth quarter of 2017 were $70.5 million, up 51% from $46.8 million in the fourth quarter of 2016.
NEW YORK, NY / ACCESSWIRE / February 8, 2018 / Innoviva, Inc. (NASDAQ: INVA ) will be discussing their earnings results in their Q4 Earnings Call to be held on February 8, 2018 at 5:00 PM Eastern Time. ...
Innoviva, Inc. announced today that it will report financial results for the fourth quarter and year ended December 31, 2017 after market close on February 8, 2017. Following the earnings release, Innoviva management will host a webcast and conference call at 5:00 p.m.
GlaxoSmithKline plc and Innoviva, Inc. today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use has issued a positive opinion recommending a label update for the use of once-daily Relvar Ellipta , an inhaled corticosteroid / long-acting β2-agonist combination, in patients whose asthma is already adequately controlled on both an inhaled corticosteroid and long-acting ...